Developer docs
API playgroundTry for free, no card

Search company profiles

Curatis

Full company profile

uuid0005iiq

Namestring
Curatis
Legal namestring
Curatis Holding AG / Curatis AG
Websiteurl
curatis.com
Company typeenum
Private
Founded yearint
2002
Descriptiontext

Curatis is a Swiss specialty pharmaceutical company, publicly listed on the Swiss exchange (swx:CURN) and headquartered in Liestal, that operates two complementary businesses: a distribution arm and a development arm. The distribution business acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland that have been developed and brought to market by third-party pharmaceutical companies, with exclusive distribution rights for more than 40 products spanning opioids, antidotes, oncology supportive care, and rare-disease therapies. The development business targets compounds with pre-existing safety and clinical efficacy data to accelerate development at lower risk and capital intensity, with a pipeline of four candidates: corticorelin (C-PTBE-01) for peritumoral brain edema (FDA-validated pivotal study design, September 2025), C-AM-01 for severe migraine with aura, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic or inflammatory orphan diseases.

Revenue is generated through product distribution in Switzerland and milestone/royalty payments from licensing deals, most notably an exclusive Japan agreement with Neupharma (March 2026) covering corticorelin, worth up to CHF 83.5 million in upfront and milestone payments plus up to 20% royalties on future Japanese sales. Reported 2025 revenue of CHF 10.8 million grew 57% versus 2024, with 13% organic growth, and management guides to approximately CHF 15 million in 2026 (~40% growth) and a break-even target for the same year. The customer base is Swiss specialist healthcare professionals and hospitals served indirectly through the distribution business, with no named enterprise customer concentration disclosed. Expansion signals include planned European footprint growth into Germany, France, the UK, and Italy, and the Neupharma partnership extending commercial reach into Japan.

Short descriptiontext

Curatis is a Swiss specialty pharmaceutical company that acquires, licenses, distributes, and promotes over 40 orphan and specialty disease medicines in Switzerland while developing a proprietary pipeline, including corticorelin for peritumoral brain edema, targeting high unmet medical needs.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersLiestal, Switzerland
HQ citystring
Liestal
HQ countrystring
Switzerland
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, orphan drug distribution, rare disease medicines, pharmaceutical pipeline development, drug licensing services
Industry1 code
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)
NAICS code3 codes
  • Pharmaceutical and Medicine Manufacturing3254
  • Drugs and Druggists' Sundries Merchant Wholesalers424210
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Wholesale-Drugs, Proprietaries & Druggists' Sundries5122
Product category
Specialty Pharmaceuticals
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1Product Distribution Business
TypeLicensing Royalties
Description

Distribution business for orphan disease and specialty care medicines: Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. The company has exclusive distribution rights for more than 40 different products in Switzerland.

curatis.com
2Pipeline Development and Licensing
TypeLicensing Royalties
Description

Development business generates revenue through milestone payments and royalties from licensing agreements. Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin in Japan worth up to CHF 83.5 million plus royalties of up to 20% on future sales.

biospace.com
Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Curatis acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland under exclusive distribution rights for more than 40 products. In parallel, it operates a development business identifying compounds with existing safety and clinical efficacy data to advance novel orphan and specialty care therapies (corticorelin/C-PTBE-01, C-AM-01, C-MOH-01, C-FI-01) toward regulatory approval and commercialization, either directly or via licensing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Revenue growth of 57% in 2025 to CHF 10.8 million from CHF 9.5 million in 2024
+3 more records
Product overview1 text field

Curatis is a Swiss specialty pharmaceutical company with two business areas: a distribution business for orphan disease and specialty care medicines, and a development business for novel orphan and specialty care drugs. The company distributes over 40 products in Switzerland including specialty care drugs, orphan drugs, and antidotes such as Actiq, Effentora (opioids for breakthrough pain), Cyanokit (for cyanide poisoning), DigiFab (for digoxin toxicity), Cuprior (for Wilson's disease), and elmiron (for bladder pain syndrome). The development pipeline includes four investigational drugs: Corticorelin (C-PTBE-01) for peritumoral brain edema (in pivotal stage), C-AM-01 for migraine prevention, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic/inflammatory orphan diseases.

Product and service11 records
1Distribution of orphan and specialty care medicines in Switzerland (portfolio of 40+ exclusive products)
CategorySpecialty pharmaceutical distribution
Description

End-to-end Swiss distribution franchise covering registration, pricing, reimbursement, and promotion of more than 40 orphan and specialty disease medicines licensed from third-party pharmaceutical companies, for sale to Swiss specialist healthcare providers, hospitals, and specialty pharmacies.

2Actiq (fentanyl citrate)
CategorySpecialty pharmaceutical distribution
Description

Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.

3Effentora (fentanyl buccal)
CategorySpecialty pharmaceutical distribution
Description

Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.

4Cyanokit (Hydroxocobalamin)
CategorySpecialty pharmaceutical distribution
Description

Antidote for cyanide poisoning distributed in Switzerland by Curatis.

5DigiFab (Digoxin Immune FAB)
CategorySpecialty pharmaceutical distribution
Description

Antidote for digoxin toxicity distributed in Switzerland by Curatis.

6Cuprior (Trientine)
CategorySpecialty pharmaceutical distribution
Description

Treatment for Wilson's disease, a rare genetic disorder causing copper accumulation, distributed in Switzerland by Curatis.

7elmiron (Pentosan Polysulfate)
CategorySpecialty pharmaceutical distribution
Description

Treatment for bladder pain syndrome/interstitial cystitis distributed in Switzerland by Curatis.

8Corticorelin (C-PTBE-01)
CategoryPharmaceutical pipeline development
Description

Proprietary pipeline candidate developed by Curatis for the treatment of peritumoral brain edema; currently advancing toward a pivotal clinical study with FDA validation of the development plan.

9C-AM-01
CategoryPharmaceutical pipeline development
Description

Proprietary pipeline candidate developed by Curatis for the prevention of severe migraine with aura; currently advancing toward a clinical Phase IIb study.

10C-MOH-01
CategoryPharmaceutical pipeline development
Description

Proprietary pipeline candidate developed by Curatis for the treatment and prevention of medication overuse headache; currently advancing toward a clinical Phase IIb study.

11C-FI-01
CategoryPharmaceutical pipeline development
Description

Proprietary pipeline candidate developed by Curatis targeting fibrotic or inflammatory orphan and ultra-orphan diseases; currently advancing toward clinical proof-of-concept.

Scale indicator8 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-01
Description

Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain edema in Japan. Neupharma receives exclusive rights to develop and commercialize the therapy in Japan, financing and conducting a pivotal clinical trial to support Japanese regulatory approval. Curatis will receive upfront and milestone payments totalling up to CHF 83.5 million, plus royalties of up to 20% on future Japanese sales. Neupharma plans to meet Japan's PMDA in mid-2026 to discuss requirements for a registration-enabling study expected to commence in 2027.

Strategic tierCoreTypeChannel Partner/ Reseller/ DistributorAnnounced on2025-10-01
Description

Curatis expanded its distribution business with Phoenix Labs through a new distribution contract to distribute four products in Switzerland starting from October 2025. These products generated approximately CHF 5 million in revenues in Switzerland in 2024 and are expected to add up to CHF 5m in additional annual revenues.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles6 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Curatis

Specialty Pharmaceuticalscuratis.com

Curatis is a Swiss specialty pharmaceutical company that acquires, licenses, distributes, and promotes over 40 orphan and specialty disease medicines in Switzerland while developing a proprietary pipeline, including corticorelin for peritumoral brain edema, targeting high unmet medical needs.

What Curatis does

Curatis is a Swiss specialty pharmaceutical company, publicly listed on the Swiss exchange (swx:CURN) and headquartered in Liestal, that operates two complementary businesses: a distribution arm and a development arm. The distribution business acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland that have been developed and brought to market by third-party pharmaceutical companies, with exclusive distribution rights for more than 40 products spanning opioids, antidotes, oncology supportive care, and rare-disease therapies. The development business targets compounds with pre-existing safety and clinical efficacy data to accelerate development at lower risk and capital intensity, with a pipeline of four candidates: corticorelin (C-PTBE-01) for peritumoral brain edema (FDA-validated pivotal study design, September 2025), C-AM-01 for severe migraine with aura, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic or inflammatory orphan diseases.

Revenue is generated through product distribution in Switzerland and milestone/royalty payments from licensing deals, most notably an exclusive Japan agreement with Neupharma (March 2026) covering corticorelin, worth up to CHF 83.5 million in upfront and milestone payments plus up to 20% royalties on future Japanese sales. Reported 2025 revenue of CHF 10.8 million grew 57% versus 2024, with 13% organic growth, and management guides to approximately CHF 15 million in 2026 (~40% growth) and a break-even target for the same year. The customer base is Swiss specialist healthcare professionals and hospitals served indirectly through the distribution business, with no named enterprise customer concentration disclosed. Expansion signals include planned European footprint growth into Germany, France, the UK, and Italy, and the Neupharma partnership extending commercial reach into Japan.

Curatis firmographics

Firmographics
Name
Curatis
Legal name
Curatis Holding AG / Curatis AG
Website
https://curatis.com
Company type
Private
Founded year
2002
Operating status
Operating
Headcount range
1–10 employees
Short description
Curatis is a Swiss specialty pharmaceutical company that acquires, licenses, distributes, and promotes over 40 orphan and specialty disease medicines in Switzerland while developing a proprietary pipeline, including corticorelin for peritumoral brain edema, targeting high unmet medical needs.
Ownership category
akta.pro rank

Curatis industry classification

Industry
Product category
Specialty Pharmaceuticals
NAICS
Pharmaceutical and Medicine Manufacturing (3254), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
akta.pro industry
PRIMARYHLAGAKAA
Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Regulatory Affairs, Quality & Compliance Services (GxP)

Keywords

  • Specialty pharmaceuticals
  • Orphan drug distribution
  • Rare disease medicines
  • Pharmaceutical pipeline development
  • Drug licensing services

Where Curatis is headquartered

Location

Headquarters

HQ city
Liestal
HQ country
Switzerland
HQ region
Europe

Offices1 record

Markets served

Curatis business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

  1. Product Distribution Business: Distribution business for orphan disease and specialty care medicines: Curatis acquires, licenses, distributes, and promotes medicines for the treatment and/or prevention of orphan and specialty diseases in Switzerland that have been developed and brought to market by third party pharmaceutical companies. The company has exclusive distribution rights for more than 40 different products in Switzerland.
  2. Pipeline Development and Licensing: Development business generates revenue through milestone payments and royalties from licensing agreements. Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin in Japan worth up to CHF 83.5 million plus royalties of up to 20% on future sales.

Go-to-market motion2 records

Distribution channels3 records

Curatis product offering

Product offering

Core offering

Curatis acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland under exclusive distribution rights for more than 40 products. In parallel, it operates a development business identifying compounds with existing safety and clinical efficacy data to advance novel orphan and specialty care therapies (corticorelin/C-PTBE-01, C-AM-01, C-MOH-01, C-FI-01) toward regulatory approval and commercialization, either directly or via licensing.

Product overview

Curatis is a Swiss specialty pharmaceutical company with two business areas: a distribution business for orphan disease and specialty care medicines, and a development business for novel orphan and specialty care drugs. The company distributes over 40 products in Switzerland including specialty care drugs, orphan drugs, and antidotes such as Actiq, Effentora (opioids for breakthrough pain), Cyanokit (for cyanide poisoning), DigiFab (for digoxin toxicity), Cuprior (for Wilson's disease), and elmiron (for bladder pain syndrome). The development pipeline includes four investigational drugs: Corticorelin (C-PTBE-01) for peritumoral brain edema (in pivotal stage), C-AM-01 for migraine prevention, C-MOH-01 for medication overuse headache, and C-FI-01 for fibrotic/inflammatory orphan diseases.

Differentiator

Problem solved

Functional benefit

Products and services

  • Distribution of orphan and specialty care medicines in Switzerland (portfolio of 40+ exclusive products) End-to-end Swiss distribution franchise covering registration, pricing, reimbursement, and promotion of more than 40 orphan and specialty disease medicines licensed from third-party pharmaceutical companies, for sale to Swiss specialist healthcare providers, hospitals, and specialty pharmacies.
  • Actiq (fentanyl citrate) Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.
  • Effentora (fentanyl buccal) Opioid medication distributed in Switzerland by Curatis for the treatment of breakthrough pain in cancer patients.
  • Cyanokit (Hydroxocobalamin) Antidote for cyanide poisoning distributed in Switzerland by Curatis.
  • DigiFab (Digoxin Immune FAB) Antidote for digoxin toxicity distributed in Switzerland by Curatis.
  • Cuprior (Trientine) Treatment for Wilson's disease, a rare genetic disorder causing copper accumulation, distributed in Switzerland by Curatis.
  • elmiron (Pentosan Polysulfate) Treatment for bladder pain syndrome/interstitial cystitis distributed in Switzerland by Curatis.
  • Corticorelin (C-PTBE-01) Proprietary pipeline candidate developed by Curatis for the treatment of peritumoral brain edema; currently advancing toward a pivotal clinical study with FDA validation of the development plan.
  • C-AM-01 Proprietary pipeline candidate developed by Curatis for the prevention of severe migraine with aura; currently advancing toward a clinical Phase IIb study.
  • C-MOH-01 Proprietary pipeline candidate developed by Curatis for the treatment and prevention of medication overuse headache; currently advancing toward a clinical Phase IIb study.
  • C-FI-01 Proprietary pipeline candidate developed by Curatis targeting fibrotic or inflammatory orphan and ultra-orphan diseases; currently advancing toward clinical proof-of-concept.

Quantifiable outcome

  • Revenue growth of 57% in 2025 to CHF 10.8 million from CHF 9.5 million in 2024
  • +3 more outcomes

Companies that use Curatis

Customer profile

Segments2 records

Ideal customer profiles2 records

Curatis technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Curatis partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • Neupharma Co., Ltd.coreStrategic or Co-development Partner · 1 March 2026Curatis signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain edema in Japan. Neupharma receives exclusive rights to develop and commercialize the therapy in Japan, financing and conducting a pivotal clinical trial to support Japanese regulatory approval. Curatis will receive upfront and milestone payments totalling up to CHF 83.5 million, plus royalties of up to 20% on future Japanese sales. Neupharma plans to meet Japan's PMDA in mid-2026 to discuss requirements for a registration-enabling study expected to commence in 2027.
  • Phoenix Labs (Ireland)coreChannel Partner/ Reseller/ Distributor · 1 October 2025Curatis expanded its distribution business with Phoenix Labs through a new distribution contract to distribute four products in Switzerland starting from October 2025. These products generated approximately CHF 5 million in revenues in Switzerland in 2024 and are expected to add up to CHF 5m in additional annual revenues.

Scale indicators8 records

Recent moves6 records

Expansion highlights6 records

Curatis competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Curatis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Curatis leadership team

Management profile

Number of profiles

Profiles6 records

Curatis funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Curatis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Curatis

What does Curatis do?

Curatis acquires, licenses, distributes, and promotes orphan and specialty disease medicines in Switzerland under exclusive distribution rights for more than 40 products. In parallel, it operates a development business identifying compounds with existing safety and clinical efficacy data to advance novel orphan and specialty care therapies (corticorelin/C-PTBE-01, C-AM-01, C-MOH-01, C-FI-01) toward regulatory approval and commercialization, either directly or via licensing.

Is Curatis a public or private company?

Curatis is a private company. It is classified as public and is currently operating.

When was Curatis founded?

Curatis was founded in 2002. It employs 1 to 10 people.

Where is Curatis based?

Curatis is headquartered in Liestal, Switzerland, in the Europe region.

How does Curatis make money?

Two revenue lines are on record. Product Distribution Business are the primary driver. The others are pipeline Development and Licensing.

Does Curatis have an API?

No public API is recorded for Curatis.

What industry is Curatis in?

Curatis's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAGAKAA, Regulatory Strategy & Global Submissions (IND/CTA/NDA/BLA/MAA). Its NAICS code is 3254 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AInvestCuratis's Record Half-Year: A Distributor Selling as a BiotechCuratis reported H1 2026 net sales of CHF 7.9 million, up 51% year over year, with operating loss narrowing to CHF 0.4 million. The company reaffirmed its 2026 break-even target and trades at a market cap of roughly CHF 107 million, priced on its corticorelin drug pipeline.AijournCuratis Increases Revenue Growth Guidance for 2026Curatis Holding AG has revised its revenue growth guidance for 2026, projecting a 40% increase compared to previous estimates of over 25%. The company expects to report approximately CHF 15 million in revenue for 2026, driven by its portfolio of over 40 products and pipeline of orphan and specialty drugs.AijournCuratis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin AchievedCuratis Holding AG reported 2025 revenues of CHF 10.8 million, representing 57% total growth and 13% organic growth in its distribution business, while its net loss narrowed to CHF 1.4 million from CHF 4.3 million in 2024. The company achieved major milestones for its lead drug candidate corticorelin, including FDA validation of its development plan in September 2025 enabling progression toward a pivotal Phase 3 trial for peritumoral brain edema. In March 2026, Curatis signed a licensing agreement for corticorelin in Japan with Neupharma Co., Ltd., with potential payments of up to CHF 83.5 million plus royalties of up to 20% on future sales.Business Wire BlogCuratis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin AchievedCuratis Holding AG reported 2025 revenues of CHF 10.8 million, representing 57% total growth with 13% organic growth in its distribution business, while its net loss narrowed significantly from CHF 4.3 million to CHF 1.4 million. The company achieved major milestones for its lead candidate corticorelin, including FDA validation of its development plan for a pivotal Phase 3 study in peritumoral brain edema. In March 2026, Curatis signed an exclusive licensing agreement with Neupharma Co., Ltd. for Japan, securing upfront and milestone payments of up to CHF 83.5 million plus royalties of up to 20% on future sales.BioSpaceCuratis: Double-Digit Revenue Growth in 2025 and Major Milestones for Corticorelin AchievedCuratis Holding AG reported 2025 revenues of CHF 10.8 million, representing 57% growth (13% organic) from CHF 9.5 million in 2024, while narrowing its net loss to CHF 1.4 million from CHF 4.3 million the prior year. The company achieved key milestones including FDA validation of its corticorelin development plan for treating peritumoral brain edema in September 2025, and concluded a licensing agreement with Japan's Neupharma Co., Ltd. in March 2026 worth up to CHF 83.5 million plus royalties of up to 20% on future sales. Curatis projects over 25% revenue growth for 2026 and aims to achieve break-even, with Neupharma planning to meet Japanese regulators in summer 2026 to discuss a pivotal trial.Pharmaceutical TechnologyCuratis, Neupharma sign development agreement for corticorelin in JapanSwitzerland-based Curatis has signed an exclusive licensing and development agreement with Neupharma for corticorelin (C-PTBE-01) to treat peritumoral brain oedema in Japan, granting Neupharma exclusive rights to develop and commercialize the therapy. Curatis is set to receive upfront and milestone payments totalling up to SFr83.5 million ($107 million), along with royalties on future Japanese sales of up to 20%, with the initial launch planned for children and adolescents. The companies plan to meet Japan's Pharmaceuticals and Medical Devices Agency (PMDA) in mid-2026 to discuss requirements for a registration-enabling study expected to commence in 2027, while Curatis continues parallel preparations for pivotal trials in Europe and the US.PharmiWeb.comCuratis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in JapanCuratis Holding AG and Neupharma Co., Ltd. have announced an exclusive licensing agreement for the development and commercialization of corticorelin (C-PTBE-01) to treat peritumoral brain edema (PTBE) in Japan, with Neupharma financing and conducting a pivotal clinical trial to support Japanese regulatory approval. Curatis will receive upfront and milestone payments totaling up to CHF 83.5 million, plus royalties of up to 20% on future Japanese sales. The drug targets a condition with no approved targeted therapies currently, with global market potential estimated to exceed USD 1 billion annually and an initial focus on children and adolescents in Japan.BioSpaceCuratis and Neupharma Announce Exclusive Licensing Agreement to Develop and Market Corticorelin (C-PTBE-01) for the Treatment of Peritumoral Brain Edema in JapanCuratis Holding AG and Neupharma Co., Ltd. announced an exclusive licensing agreement for corticorelin (C-PTBE-01), an investigational drug for peritumoral brain edema, granting Neupharma exclusive rights to develop and commercialize the treatment in Japan. Under the agreement, Neupharma will finance and conduct a pivotal clinical trial in Japan while Curatis receives upfront and milestone payments of up to CHF 83.5 million plus royalties of up to 20% on future sales. The global market potential for corticorelin is forecasted to exceed USD 1 billion annually, with approximately 60,000 eligible patients in Japan and 500,000 worldwide.Business Wire BlogCuratis Expands Distribution Business With Phoenix Labs with up to CHF 5m Additional Annual RevenuesCuratis Holding AG announced a new distribution contract with Phoenix Labs (Ireland) to distribute four products in Switzerland, starting from October 2025. The products generated approximately CHF 5 million in revenues in Switzerland in 2024.